.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Oncology

Money and Control Influence Oncologists' Use of Biosimilars

May 30th 2020

By Skylar Jeremias

Article

Abstracts presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.

Prestige BioPharma's Trastuzumab Demonstrates Equivalence

May 29th 2020

By Tony Hagen

Article

Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab, based on findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Oncology

Money and Control Influence Oncologists' Use of Biosimilars

Prestige BioPharma's Trastuzumab Demonstrates Equivalence

Biosimilars in Oncology: Future Directions

Competition in the Biosimilar Marketplace

Biosimilars in Oncology: Long-Term Financial Benefit

Economic Impact of Biosimilars in Oncology

Incorporating Biosimilars in Oncology: Working Collaboratively

Strategies for Incorporating Biosimilars Into Care Plans

Multiple Biosimilars for a Single-Reference Biologic

Where Do Biosimilars Fit in to the Treatment Landscape?